Evonik Cuts Shareholder Payout Amid Restructuring Drive

The German specialty chemicals group Evonik has met its profit targets for 2025, but investors are facing a reduction in returns. As a stringent cost-saving program takes effect, the company’s board has lowered its dividend and adopted a cautious stance for the current business year. This raises questions about the resilience of the MDax-listed firm as it navigates a prolonged industry downturn.

Dividend Policy Shifted to Preserve Capital

In a move to bolster financial flexibility, Evonik’s management has overhauled its dividend framework. Going forward, the company plans to distribute between 40% and 60% of its adjusted net income. For the concluded 2025 fiscal year, this policy translates into a proposed dividend of €1.00 per share, down from the €1.17 per share paid out the previous year.

This adjustment is part of the broader “Evonik Tailor Made” transformation initiative. Scheduled for completion by 2026, the program is designed to yield annual savings of approximately €400 million. The restructuring carries a significant human cost, with plans to eliminate up to 2,000 positions globally, the majority of which are located in Germany.

Earnings Hold Firm Despite Revenue Decline

Evonik’s full-year 2025 results present a dichotomy. On an operational level, the company delivered as promised: adjusted EBITDA came in at €1.87 billion, aligning closely with guidance. Net income even saw a modest increase to €265 million.

Should investors sell immediately? Or is it worth buying Evonik?

The top-line figures, however, underscore the sector’s persistent challenges. Group sales receded by 7% year-on-year to €14.1 billion. The “Advanced Technologies” segment was a particular area of weakness, recording declines in both revenue and margin. The share price, which has lost over 33% in the past twelve months and currently trades around €13.92, reflects this ongoing growth concern.

Leadership Gap and Cautious Forecast Add Uncertainty

An unresolved element of uncertainty is the vacant position on the executive board for finance. The role has been open since September 2025 and is not expected to be filled until the Annual General Meeting in June—an unusually long interim period during a challenging market environment.

For the 2026 fiscal year, Evonik has slightly tempered its sales outlook, now projecting a range of €13.5 billion to €14.5 billion. Management anticipates adjusted EBITDA will land between €1.7 billion and €2.0 billion. This wide guidance bracket highlights the limited visibility in a market still characterized by elevated energy costs and global overcapacity.

Conclusion

While Evonik has delivered on its profit commitments, this stability has been achieved through severe cuts to both its workforce and shareholder returns. The company is in a difficult transitional phase, lacking clear revenue growth drivers. The progress of its savings plan and the introduction of the new finance chief at the Annual General Meeting on June 3, 2026, will be pivotal for the stock’s future trajectory.